StrideBio Announces Closing of $81.5M Series B Financing
- Tuesday, March 16, 2021, 7:00
- Finance
- Add a comment
RESEARCH TRIANGLE PARK, N.C., March 16, 2021 /PRNewswire/ — StrideBio, Inc., a leading developer of novel engineered adeno-associated virus (AAV) based gene therapies, today announced the closing of an oversubscribed Series B funding round, which raised $81.5 million. The financing was…
About the Author
adminasapcorp has written 41562 stories on this site.